7AY1 Stock Chart & Stats
€0.86
>-€0.01(-0.14%)
At close: 4:00 PM EDT
€0.86
>-€0.01(-0.14%)
Day’s Range― - ―
52-Week Range€0.63 - €1.43
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€30.84M
Enterprise Value-€3.88M
Total Cash (Recent Filing)€36.47M
Total Debt (Recent Filing)€1.34M
Price to Earnings (P/E)3.1
Beta0.51
Next Earnings
Nov 23, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.11Price Target Upside262.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)€30.35M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and stronger equity capitalization improve Actinium’s solvency and financial flexibility relative to many biotechnology peers. This reduces near-term balance-sheet pressure and gives the company a more durable base from which to fund clinical development and pursue strategic opportunities.
Improved Reported ResultsThe latest TTM period shows a meaningful improvement from several years of heavy losses, indicating progress in reported operating results. If sustained, the revenue and earnings step-up could strengthen access to capital and support continued investment in Actinium’s clinical pipeline.
Pipeline IP And Capacity ExpansionBroader Actimab-A patent protection can extend the commercial protection and strategic value of the targeted radiotherapy platform. Additional manufacturing capacity also supports execution of company-sponsored and NCI-related studies as the program approaches important clinical milestones.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not currently self-funding, despite the latest reported net income. Continued clinical spending therefore may require additional financing, creating dilution or funding pressure if cash burn remains elevated over coming quarters.
Thin And Volatile ProfitabilityThe very thin gross margin provides limited cushion to absorb operating expenses, while the historical pattern of weak and volatile margins makes the latest earnings improvement difficult to assess as durable. This limits confidence in sustainable profitability until underlying economics improve.
NYSE American Compliance RiskOngoing exchange compliance issues create a structural corporate risk beyond normal clinical execution. Although the approved plan extends the remediation period, failure to meet NYSE American standards could reduce market access, complicate financing, and weaken the company’s strategic flexibility.
Actinium Pharmaceuticals News
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €0.63 and its highest was €1.43 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is €30.84M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 41 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -€0.165 earnings per share for the quarter, missing the consensus estimate of -€0.162 by -€0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -0.21.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.165 in its last earnings report, missing expectations of -€0.162. Following the earnings report the stock price went up 0.612%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:7AY1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinium Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
83.42%
Trailing 12-Months
Asset Growth
-36.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
7AY1 Stock 12 Month Forecast
Average Price Target
€3.11
▲(262.10% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Marker Therapeutics
―
Celularity
―